AR019150A1 - Composicion farmaceutica estabilizada que contiene un componente de droga que comprende un componente de droga que comprende un inhibidor de ace, unestabilizador y un agente de minimizacion de hidrolisis, tableta que la contiene y proceso para estabilizar una droga - Google Patents
Composicion farmaceutica estabilizada que contiene un componente de droga que comprende un componente de droga que comprende un inhibidor de ace, unestabilizador y un agente de minimizacion de hidrolisis, tableta que la contiene y proceso para estabilizar una drogaInfo
- Publication number
- AR019150A1 AR019150A1 ARP990102642A ARP990102642A AR019150A1 AR 019150 A1 AR019150 A1 AR 019150A1 AR P990102642 A ARP990102642 A AR P990102642A AR P990102642 A ARP990102642 A AR P990102642A AR 019150 A1 AR019150 A1 AR 019150A1
- Authority
- AR
- Argentina
- Prior art keywords
- ace inhibitor
- drug component
- hydrolysis
- magnesium oxide
- pharmaceutical composition
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title abstract 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title abstract 5
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 230000007062 hydrolysis Effects 0.000 title abstract 4
- 238000006460 hydrolysis reaction Methods 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003381 stabilizer Substances 0.000 title abstract 2
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 4
- 239000000395 magnesium oxide Substances 0.000 abstract 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 102000015427 Angiotensins Human genes 0.000 abstract 1
- 108010064733 Angiotensins Proteins 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000002845 discoloration Methods 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 229940125532 enzyme inhibitor Drugs 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 abstract 1
- 229960001455 quinapril Drugs 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones que contienen inhibidor de ACE, estabilizadas mediante la presencia de oxido de magnesio. Preferentemente, el inhibidor de la enzimaconversora de Angiotensina quinapril, es protegido de ciertas formas de degradacion, como la ciclacion,hidrolisis, decoloracion oxidativa, etc, cuando seprepara en una composicion farmacéutica compuesta esencialmente por oxido de magnesio como el agente estabilizador. La presencia de oxido de magnesio tambiénse presta para condiciones deprocesamiento favorables durante la fabricacion de las composiciones que contienen inhibidor de ACE, especialmente procesamientomediante granulacion en medio humedo. También contienen un agente que minimiza la hidrolisis del inhibidor de ACE, talcomo un sacárido , un diurético, fosfatodicálcico o rellenos. Se incluye la tableta que contiene dicha composicion y el proceso para estabilizar dichas drogas, que tiene lugar en las composiciones dela presente, que comprende poner en contacto ladroga con oxido de m agnesio y un agente de minimizacion de hidrolisis. Dicho inhibidor de ACE es de formulageneral (I).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8828098P | 1998-06-05 | 1998-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR019150A1 true AR019150A1 (es) | 2001-12-26 |
Family
ID=22210458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102642A AR019150A1 (es) | 1998-06-05 | 1999-06-04 | Composicion farmaceutica estabilizada que contiene un componente de droga que comprende un componente de droga que comprende un inhibidor de ace, unestabilizador y un agente de minimizacion de hidrolisis, tableta que la contiene y proceso para estabilizar una droga |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US6417196B1 (es) |
| EP (1) | EP1083931B1 (es) |
| JP (1) | JP3727848B2 (es) |
| KR (1) | KR20010052557A (es) |
| CN (1) | CN1144598C (es) |
| AR (1) | AR019150A1 (es) |
| AT (1) | ATE295184T1 (es) |
| AU (1) | AU755616B2 (es) |
| BR (1) | BR9910947A (es) |
| CA (1) | CA2330581A1 (es) |
| CO (1) | CO5011043A1 (es) |
| DE (1) | DE69925269T2 (es) |
| ES (1) | ES2242398T3 (es) |
| GT (1) | GT199900079A (es) |
| HK (1) | HK1038879B (es) |
| HN (1) | HN1999000088A (es) |
| HU (1) | HUP0102260A3 (es) |
| ID (1) | ID27398A (es) |
| IL (1) | IL139590A0 (es) |
| IS (1) | IS2270B (es) |
| MY (1) | MY119667A (es) |
| NO (1) | NO20006148D0 (es) |
| NZ (1) | NZ508544A (es) |
| PA (1) | PA8475001A1 (es) |
| PE (1) | PE20000543A1 (es) |
| PL (1) | PL344586A1 (es) |
| SV (1) | SV1999000072A (es) |
| TR (1) | TR200003600T2 (es) |
| TW (1) | TW565455B (es) |
| UY (1) | UY25546A1 (es) |
| WO (1) | WO1999062560A1 (es) |
| ZA (1) | ZA200006537B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0102260A3 (en) * | 1998-06-05 | 2002-12-28 | Warner Lambert Co | Stabilization of compositions containing ace inhibitors using magnesium oxide |
| NZ333206A (en) * | 1998-12-08 | 2000-07-28 | Bernard Charles Sherman | Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor |
| GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| US7867514B2 (en) * | 2000-05-24 | 2011-01-11 | Otsuka Pharmaceutical Co., Ltd. | Method for stabilizing preparation |
| US20050118259A1 (en) * | 2002-01-15 | 2005-06-02 | Renir Eyjolfsson | Formulations of quinapril and related ace nhibitors |
| US20030157165A1 (en) * | 2002-02-01 | 2003-08-21 | Sherman Bernard Charles | Stable saccharide-free tablets comprising a salt of quinapril or moexipril |
| WO2004073729A1 (ja) * | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
| EP1607117A4 (en) | 2003-03-27 | 2007-10-24 | Bioactis Ltd | APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE |
| CZ298224B6 (cs) * | 2003-04-29 | 2007-07-25 | Pliva Istrazivanje I Razvoj D.O.O. | Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby |
| ATE424192T1 (de) * | 2003-06-26 | 2009-03-15 | Teva Pharma | Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten |
| WO2006016530A1 (ja) * | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
| US8779175B2 (en) | 2004-10-25 | 2014-07-15 | Synthonics, Inc. | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
| US7799937B2 (en) | 2004-10-25 | 2010-09-21 | Synthonics, Inc. | Metal coordinated compositions |
| US20060141054A1 (en) * | 2004-10-25 | 2006-06-29 | Thomas Piccariello | Metal coordinated compositions |
| ITMI20060026A1 (it) * | 2006-01-10 | 2007-07-11 | Truffini & Regge Farmaceutici Srl | Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| US20070232680A1 (en) * | 2006-04-04 | 2007-10-04 | Vijayabhaskar Bolugoddu | Preparation of ramipril and stable pharmaceutical compositions |
| MX2008013374A (es) * | 2006-04-19 | 2008-11-12 | Teva Pharma | Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3.0]-octano-3-carboxilico. |
| WO2008000040A1 (en) * | 2006-06-30 | 2008-01-03 | Alphapharm Pty Ltd | A stabilised composition comprising ace inhibitors |
| US20080071141A1 (en) * | 2006-09-18 | 2008-03-20 | Abhisuek Gattani | Method and apparatus for measuring attributes of an anatomical feature during a medical procedure |
| WO2008078730A1 (ja) | 2006-12-26 | 2008-07-03 | Translational Research, Ltd. | 経鼻投与用製剤 |
| WO2008132756A1 (en) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
| JP5113476B2 (ja) * | 2007-10-09 | 2013-01-09 | 沢井製薬株式会社 | 保存安定性に優れた塩酸テモカプリルの錠剤 |
| US9101539B2 (en) * | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
| TR200906322A2 (tr) | 2009-08-17 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Çözünürlük ve stabilite özellikleri geliştirilmiş granüller. |
| ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| CN102512656B (zh) * | 2011-12-27 | 2013-11-27 | 天津市嵩锐医药科技有限公司 | 盐酸喹那普利药物组合物 |
| US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320029A (en) * | 1967-05-16 | Method of preparing magnesia | ||
| IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| US4344949A (en) * | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| US4425355A (en) * | 1981-02-17 | 1984-01-10 | Warner-Lambert Company | Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids |
| US4793998A (en) * | 1986-10-20 | 1988-12-27 | Warner-Lambert Company | Stabilized drug compositions |
| US4830853A (en) | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
| US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
| US4830583A (en) * | 1988-03-02 | 1989-05-16 | Sri International | Fluid motor-pumping apparatus and system |
| US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| HU222489B1 (hu) * | 1990-07-25 | 2003-07-28 | Novartis Ag. | Stabilizált gyógyszerkészítmények és eljárás az előállításukra |
| IT1251153B (it) * | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
| JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| HUP0102260A3 (en) * | 1998-06-05 | 2002-12-28 | Warner Lambert Co | Stabilization of compositions containing ace inhibitors using magnesium oxide |
| NZ333206A (en) * | 1998-12-08 | 2000-07-28 | Bernard Charles Sherman | Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor |
-
1999
- 1999-05-10 HU HU0102260A patent/HUP0102260A3/hu unknown
- 1999-05-10 NZ NZ508544A patent/NZ508544A/xx unknown
- 1999-05-10 ES ES99922899T patent/ES2242398T3/es not_active Expired - Lifetime
- 1999-05-10 PL PL99344586A patent/PL344586A1/xx not_active Application Discontinuation
- 1999-05-10 TR TR2000/03600T patent/TR200003600T2/xx unknown
- 1999-05-10 EP EP99922899A patent/EP1083931B1/en not_active Revoked
- 1999-05-10 IL IL13959099A patent/IL139590A0/xx not_active IP Right Cessation
- 1999-05-10 ID IDW20002515A patent/ID27398A/id unknown
- 1999-05-10 WO PCT/US1999/010189 patent/WO1999062560A1/en active IP Right Grant
- 1999-05-10 KR KR1020007013714A patent/KR20010052557A/ko not_active Application Discontinuation
- 1999-05-10 JP JP2000551814A patent/JP3727848B2/ja not_active Expired - Fee Related
- 1999-05-10 CA CA002330581A patent/CA2330581A1/en not_active Abandoned
- 1999-05-10 US US09/700,883 patent/US6417196B1/en not_active Expired - Fee Related
- 1999-05-10 AU AU39793/99A patent/AU755616B2/en not_active Ceased
- 1999-05-10 AT AT99922899T patent/ATE295184T1/de not_active IP Right Cessation
- 1999-05-10 DE DE69925269T patent/DE69925269T2/de not_active Revoked
- 1999-05-10 CN CNB998070262A patent/CN1144598C/zh not_active Expired - Fee Related
- 1999-05-10 BR BR9910947-6A patent/BR9910947A/pt not_active Application Discontinuation
- 1999-05-18 TW TW088108107A patent/TW565455B/zh not_active IP Right Cessation
- 1999-06-03 HN HN1999000088A patent/HN1999000088A/es unknown
- 1999-06-03 MY MYPI99002229A patent/MY119667A/en unknown
- 1999-06-04 SV SV1999000072A patent/SV1999000072A/es not_active Application Discontinuation
- 1999-06-04 PA PA19998475001A patent/PA8475001A1/es unknown
- 1999-06-04 AR ARP990102642A patent/AR019150A1/es not_active Application Discontinuation
- 1999-06-04 CO CO99035274A patent/CO5011043A1/es unknown
- 1999-06-04 UY UY25546A patent/UY25546A1/es not_active IP Right Cessation
- 1999-06-04 GT GT199900079A patent/GT199900079A/es unknown
- 1999-06-04 PE PE1999000475A patent/PE20000543A1/es not_active Application Discontinuation
-
2000
- 2000-11-10 ZA ZA200006537A patent/ZA200006537B/en unknown
- 2000-11-10 IS IS5712A patent/IS2270B/is unknown
- 2000-12-04 NO NO20006148A patent/NO20006148D0/no unknown
-
2002
- 2002-01-18 HK HK02100407.5A patent/HK1038879B/zh not_active IP Right Cessation
- 2002-04-22 US US10/127,181 patent/US7015232B2/en not_active Expired - Fee Related
-
2005
- 2005-12-15 US US11/313,123 patent/US20060106057A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR019150A1 (es) | Composicion farmaceutica estabilizada que contiene un componente de droga que comprende un componente de droga que comprende un inhibidor de ace, unestabilizador y un agente de minimizacion de hidrolisis, tableta que la contiene y proceso para estabilizar una droga | |
| NO20052690L (no) | Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke. | |
| DK2382970T3 (da) | Stabile farmaceutiske sammensætninger, der indeholder 7-substitueret-3,5-dihydroxyheptansyrer eller 7-substitueret-3,5-dihydroxyheptensyrer | |
| EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| BRPI0415121A (pt) | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida | |
| ECSP044935A (es) | Inhibidores de la dipeptidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
| BRPI0600194A (pt) | composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas | |
| SV2003001106A (es) | Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco ref.pc11846 | |
| EA200601553A1 (ru) | Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды | |
| UY25055A1 (es) | Formulaciones farmacéuticas que contienen voriconazol | |
| ATE277929T1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
| BRPI0515596A (pt) | composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero | |
| ATE388951T1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
| BR0011130A (pt) | Inibidores de metaloproteases | |
| ME00181B (me) | Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primjena | |
| ATE433989T1 (de) | Pharmazeutisch wirksame uridinester | |
| ATE310089T1 (de) | Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen | |
| NO20040153L (no) | Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes | |
| EE05124B1 (et) | Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine | |
| HUE009867T2 (es) | ||
| NO20004306L (no) | Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat | |
| TW200505487A (en) | Composition for injection | |
| BR9808722A (pt) | Composições farmacêuticas de tizoxanida e nitazoxanida | |
| ITMI20052515A1 (it) | Formulazione farmaceutica per il trattamento della osteoartrite | |
| CR8974A (es) | Composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |